Library · Skin & hair · Cervical dystonia, glabellar lines
DaxibotulinumtoxinA
DaxibotulinumtoxinA-lanm, Daxxify
150-kDa botulinum toxin type A formulated with a stabilizing peptide (RTP004) that removes human serum albumin and allows room-temperature storage. FDA-approved in 2022 for moderate-to-severe glabellar lines, with effects lasting a median of six months, up to nine in some patients.
Research score 87/100. Reference only, not a dose.
- Muscle Relaxation
- Anti-aging
- Cosmetic
- US status
- Prescription Only
- Approval
- FDA Approved (2022)
- Evidence
- SAKURA trials: median 168-day (24-week) duration maintaining 'none' or 'mild' severity
- Research score
- 87 / 100
- Indication
- Glabellar lines (frown lines)
- Origin
- United States
- Source category
- Skin & Dermatology
- Status group
- Approved / prescription
Mechanism
Cleaves the SNAP25 protein needed for acetylcholine release at the neuromuscular junction, dose-dependently reducing muscle contraction.
Safety file
Similar safety profile to other botulinum toxin products.
- Injection site reactions
- Headache
- Facial paresis